Does MassHealth cover Zepbound, Wegovy or Ozempic in 2026?

What MassHealth still covers, use by use

MassHealth's notice puts it plainly: any drug used off label for weight loss is not payable ^[1]. What remains are specific medical reasons, each with its own BMI floor.

MassHealth GLP-1 coverage after July 2, 2026, by use

Use	What MassHealth requires	Drug MassHealth prefers	Source
Weight loss only	Not covered, for any member or plan type	None	[1]
Heart disease (lowering major cardiac event risk)	Prior authorization; BMI over 27 and established cardiovascular disease	Wegovy	[1]
Obstructive sleep apnea	Prior authorization; BMI over 30 and moderate to severe sleep apnea	Wegovy; continuing Zepbound requires a Wegovy trial	[1]
MASH	Prior authorization	Wegovy	[1]
Members under 21	Covered when medically necessary under EPSDT	Not specified	[1]
Type 2 diabetes	Generally pays at the pharmacy with a diabetes diagnosis	Ozempic, Mounjaro, Trulicity, Victoza	[2]

Zepbound after July 2026: the Wegovy step

Zepbound lost its preferred status on July 3, 2026 ^[1]. Approved Zepbound prior authorizations for a covered use that ran past July 2, 2026 were replaced with Wegovy authorizations for the rest of the original approval, and members needed a new Wegovy prescription ^[1]. Prior authorizations for continued Zepbound treatment past July 2, 2026 require a trial of Wegovy for all patients ^[1].

The step applies to sleep apnea too, and that creates an odd fit. Zepbound's FDA label includes moderate to severe obstructive sleep apnea in adults with obesity ^[11]; Wegovy's label does not list sleep apnea ^[12]. MassHealth still names Wegovy as the sole preferred drug for every remaining use, including its sleep apnea criterion ^[1]. A member with sleep apnea should ask the prescriber how the Wegovy trial will be documented before a Zepbound request goes in.

Timeline of MassHealth GLP-1 changes

1. Jan 1, 2025: MassHealth's drug list says Saxenda and Wegovy stopped being covered for adult overweight or obesity, leaving Zepbound as the preferred weight-loss GLP-1. Wegovy stayed available for heart risk ^[5].
2. Jan 14, 2026: Pharmacy Facts 269 announced that, from Feb 17, 2026, Wegovy would join Zepbound as a preferred drug at parity, and Ozempic would join Mounjaro as preferred for diabetes ^[3].
3. Feb 17, 2026: Adult criteria tightened to a BMI of 35 or more; a BMI of 30 to under 35 with heart failure with preserved ejection fraction, high blood pressure uncontrolled despite medication, stage 3a or worse kidney disease, or moderate or severe sleep apnea; or a BMI of 27 or more with type 2 diabetes or prediabetes (using a diabetes GLP-1), a prior heart attack or stroke, symptomatic peripheral artery disease, or MASH with moderate to advanced fibrosis ^[3].
4. Mar 12, 2026: Pharmacy Facts 271 announced the end of weight-loss coverage on July 3, 2026, and set prior authorizations submitted before Feb 17 to expire July 2 ^[4].
5. May 13, 2026: MassHealth issued a corrected Pharmacy Facts 276 with the final list of drugs, the remaining covered uses and Wegovy as the sole preferred drug ^[1].
6. June 23, 2026: WBUR reported, citing state officials, that the change would affect at least 22,000 people and save $15 million a year ^[6]. Boston.com reported it began as a proposal in Gov. Maura Healey's fiscal 2027 budget ^[7].
7. July 3, 2026: Coverage of anti-obesity drugs for weight loss ended ^[1].

Who the change reaches

Every MassHealth member is covered by the rule, whether in fee-for-service, a managed care organization, an ACO plan (ACPP or PCACO), the PCC Plan, PACE, SCO or One Care ^[1]. MassHealth and CHIP enrolled 1,525,312 people in June 2026, 1,352,133 of them in Medicaid alone, according to KFF's tables of federal data ^[10]. Rhode Island Current, noting that Massachusetts ended obesity-only coverage on July 3, called Rhode Island at least the seventh state in 2026 to cease or not renew Medicaid GLP-1 obesity coverage ^[8].

Private coverage in the state moved first. For commercial members with its pharmacy benefits and members in certain self-insured accounts, Blue Cross Blue Shield of Massachusetts covers GLP-1s only for type 2 diabetes starting Jan 1, 2026, as members renew, with no exceptions or appeals; obesity coverage continues only if the employer buys a rider ^[9]. Details are on our Blue Cross Blue Shield GLP-1 coverage page. WBUR also reported that the state Group Insurance Commission, which provides benefits to public employees, planned to stop covering these drugs for weight loss ^[6].

In our own search on Oct 18, 2026, we could not confirm whether Massachusetts applied to the federal BALANCE model for Medicaid GLP-1 coverage. For local care and cash-pay options, see medical weight loss in Boston.

Your next steps

Check whether a medical use fits

• Established heart disease and a BMI over 27: a Wegovy request for major cardiac event risk can be filed ^[1]. Wegovy's label includes this use ^[12].
• Moderate to severe sleep apnea and a BMI over 30: the request starts with Wegovy; Zepbound follows only after a Wegovy trial ^[1].
• MASH: ask whether the liver diagnosis and fibrosis records support a Wegovy request ^{[1] [12]}.
• Diabetes or prediabetes on a weight-loss GLP-1: MassHealth says that for continued coverage from July 3, 2026, these members should be switched to a diabetes GLP-1 such as Ozempic or Mounjaro ^[2].
• Under 21: requests can be approved when medically necessary under EPSDT ^[1].

If MassHealth denies or cuts back a request

MassHealth members can appeal a denied or modified prior authorization through a fair hearing. The Board of Hearings must receive the signed request within 60 calendar days of the date you received the notice ^[15]. You can fax the signed form to 617-887-8797, mail it to the Office of Medicaid, Board of Hearings, 1 Enterprise Drive, 3rd Floor, Quincy, MA 02171, email it, or call MassHealth Customer Service at (800) 841-2900 (TTY 711) ^[15]. Weight loss on its own is no longer payable ^[1], so a hearing makes most sense when a heart, sleep apnea or MASH request was refused. Managed care plan members should read their notice for any plan-level appeal step; the state's page does not say whether one comes first.

Paying without MassHealth

• Zepbound on LillyDirect: $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5 to 15 mg when each refill comes within 45 days; otherwise $499 at 7.5 mg and $699 at 10 to 15 mg. Checked Oct 17, 2026 ^[14].
• Wegovy pen on NovoCare: $349 a month at any standard dose, with $199 for a new patient's first two fills of the two lowest doses through Dec 31, 2026; the 7.2 mg pen is $399. Checked Oct 17, 2026 ^[13].
• Wegovy pill on NovoCare: $149 to $299 a month depending on dose. Checked Oct 17, 2026 ^[13].
• Copay cards: Lilly's and Novo Nordisk's $25 cards are for commercial insurance and exclude government programs such as Medicaid ^{[17] [13]}.

Compare channels on Zepbound cost and Wegovy cost. If you also have Medicare Part D, the Medicare GLP-1 Bridge covers Wegovy and the Zepbound KwikPen for weight management at $50 a month for those who qualify ^[16]; see Medicare GLP-1 coverage. California made a similar cut earlier; compare Medi-Cal GLP-1 coverage, and see GLP-1 insurance coverage for employer plans.

See Medicaid GLP-1 rules in all 50 states